ALNY
Alnylam Pharmaceuticals Inc
Halal Rating :
Last Price
$246.36
Last updated:
Market Cap
-
7D Change
-4.61%
1 Year Change
33.95%
Company Overview
Industries
Exchange
Next Earnings Date
Alnylam Pharmaceuticals is a biopharmaceutical company focused on the discovery, development, and commercialization of RNA interference (RNAi) therapeutics. The company develops innovative treatments for genetic diseases, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system diseases. Their primary business involves researching and developing novel therapeutic products using their RNAi technology platform.
Use of Interest
| Reporting Date | Total Revenue | Total Operating Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|---|---|---|---|---|---|
| Sept. 30, 2024 | $500.92m | $612.2m | - | $34.38m | 0.00% | 5.62% |
| June 30, 2024 | $659.83m | $644.47m | - | $33.26m | 0.00% | 5.16% |
| March 31, 2024 | $494.33m | $573.02m | - | $35.25m | 0.00% | 6.15% |
Company Impact
Help us evaluate Alnylam Pharmaceuticals Inc's impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.